Investigators sought to assess the link between treatment for thyroid cancer and subsequent cardiac and vascular complications.
In an orthotopic anaplastic thyroid cancer model, hypofractionated radiotherapy is superior to conventionally fractionated radiotherapy.
Study data showed 57% of evaluable patients (N=23) had a partial response and 4% achieved a complete response. Among the 14 responders, 64% did not have significant tumor growths for ≥6 months.
Survivors of thyroid cancer have a higher risk of developing age-associated diseases compared with patients who never had cancer, particularly if they were younger than 40 years at the time of diagnosis.
No clear effect in most cases of a second radioactive iodine (RAI) treatment in patients with differentiated thyroid cancer with biochemical or structural regional incomplete response to initial thyroidectomy and RAI therapy.
No regional or distant metastases developed during active surveillance in low-risk patients.
Revised ATA guidelines have led to an increased interest in risk-adopted management strategies for differentiated thyroid cancer.
Irregular users of thyroxine were less likely to develop thyroid cancer compared to regular users.
Stroke risk with I-131 therapy for thyroid cancer was examined via 2 cohorts using 1:1 propensity score matching.
Thyroid cancer screening in asymptomatic adults was given a D recommendation because of the negative effects of screening outweighing any benefits.
Multiple studies at ENDO 2017 highlighted the dangers linked to both environmental toxin and common household chemical exposure.
Patients with government subsidized or self-pay insurance were less likely to undergo thyroidectomy for thyroid cancer.
Increases in papillary thyroid cancer were most common between 1974 and 2013.
Elemental calcium — found in cow's milk — significantly limits a person's ability to absorb oral levothyroxine.
Younger survivors of thyroid cancer are at increased risk for certain types of health problems later in life.
For patients with unresected anaplastic thyroid carcinoma, overall survival is poor, but radiation therapy dose is associated with improved survival.
Widespread routine thyroid cancer screening can lead to overdiagnosis and overtreatment, according to the statement.
Does core-needle biopsy perform better than repeat fine-needle aspiration for evaluating thyroid nodules?
CDC27 mutations may be associated with less aggressive behavior while SLC25A5 mutations may be associated with more aggressive behavior in papillary thyroid carcinomas.
The first-in-class compound CUDC-907, which is being tested for multiple myeloma and refractory lymphoma, may be promising for anaplastic thyroid cancer and poorly differentiated thyroid cancer.
Long-term recurrence rates appear to be low following the use of recombinant human thyrotropin for postoperative ablation in low-risk thyroid cancer.
Initiating treatment with the mTor inhibitor everolimus followed by the somatostatin analogue pasireotide may be beneficial in advanced thyroid cancer.
A new study has validated the American Thyroid Association sonographic pattern for selection of thyroid nodules undergoing ultrasound-guided fine needle aspiration.
Active surveillance in low-risk thyroid cancer may be better than immediate surgery in some patients.
Despite side effects, patients with differentiated thyroid cancer taking lenvatinib may experience better outcomes with close monitoring.
Liquid biopsy may prevent the need for unnecessary biopsies in patients with medullary thyroid carcinoma.
Researchers have identified estimates for risk of occult nodal disease of patients with papillary thyroid cancer who have undergone surgery.
More imaging tests after treatment does not always lead to an improvement in thyroid cancer patients' chances of survival.
There were no effective therapeutic options for advanced thyroid cancer until 5 years ago.
The recent increase may be caused by an 'epidemic of diagnosis,' not harmful tumors, researchers said.
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- AMA: Federal Government Must Tackle Rising Insulin Prices
- Diabetes Medication Reconciliation May Reduce Risk of ED Visits